Karl Richard Gibson active positions
| Companies | Position | Start | End |
|---|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Chief Tech/Sci/R&D Officer | 2011-07-26 | - |
| Founder | 2011-07-26 | - | |
| Sandexis LLP | Founder | - | - |
Career history of Karl Richard Gibson
Training of Karl Richard Gibson
| University of Cambridge | Doctorate Degree |
Statistics
International
| United Kingdom | 4 |
Operational
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Sandexis LLP |
- Stock Market
- Insiders
- Karl Richard Gibson
- Experience
